These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32154750)

  • 1. Device profile of the Resolute Onyx Zotarolimus eluting coronary stent system for the treatment of coronary artery disease: overview of its safety and efficacy.
    Blum M; Cao D; Mehran R
    Expert Rev Med Devices; 2020 Apr; 17(4):257-265. PubMed ID: 32154750
    [No Abstract]   [Full Text] [Related]  

  • 2. Thin composite wire strut, durable polymer-coated (Resolute Onyx) versus ultrathin cobalt-chromium strut, bioresorbable polymer-coated (Orsiro) drug-eluting stents in allcomers with coronary artery disease (BIONYX): an international, single-blind, randomised non-inferiority trial.
    von Birgelen C; Zocca P; Buiten RA; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Anthonio RL; Stoel MG; Somi S; Hartmann M; Linssen GCM; Doggen CJM; Kok MM
    Lancet; 2018 Oct; 392(10154):1235-1245. PubMed ID: 30253879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial.
    Price MJ; Shlofmitz RA; Spriggs DJ; Haldis TA; Myers P; Popma Almonacid A; Maehara A; Dauler M; Peng Y; Mehran R
    Catheter Cardiovasc Interv; 2018 Aug; 92(2):253-259. PubMed ID: 28940882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
    Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
    JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter.
    Price MJ; Saito S; Shlofmitz RA; Spriggs DJ; Attubato M; McLaurin B; Popma Almonacid A; Brar S; Liu M; Moe E; Mehran R
    JACC Cardiovasc Interv; 2017 Jul; 10(14):1381-1388. PubMed ID: 28728650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review.
    Yang JX; Yeh RW
    Future Cardiol; 2018 May; 14(3):251-267. PubMed ID: 29448810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zotarolimus- and paclitaxel-eluting stents in an all-comer population in China: the RESOLUTE China randomized controlled trial.
    Xu B; Yang Y; Yuan Z; Du Z; Wong SC; Généreux P; Lu S;
    JACC Cardiovasc Interv; 2013 Jul; 6(7):664-70. PubMed ID: 23523240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program.
    Silber S; Serruys PW; Leon MB; Meredith IT; Windecker S; Neumann FJ; Belardi J; Widimsky P; Massaro J; Novack V; Yeung AC; Saito S; Mauri L
    JACC Cardiovasc Interv; 2013 Apr; 6(4):357-68. PubMed ID: 23523454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two zotarolimus-eluting stent generations: a meta-analysis of 12 randomised trials versus other limus-eluting stents and an adjusted indirect comparison.
    Cassese S; Ndrepepa G; King LA; Tada T; Fusaro M; Kastrati A
    Heart; 2012 Nov; 98(22):1632-40. PubMed ID: 22949487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
    Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
    Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
    J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
    Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
    JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DynamX sirolimus-eluting Bioadaptor versus the zotarolimus-eluting Resolute Onyx stent in patients with de novo coronary artery lesions: Design and rationale of the multi-center, international, randomized BIODAPTOR-RCT.
    Saito S; Nef HM; Webster M; Verheye S;
    Cardiovasc Revasc Med; 2023 Oct; 55():76-82. PubMed ID: 37479544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial.
    von Birgelen C; Kok MM; van der Heijden LC; Danse PW; Schotborgh CE; Scholte M; Gin RMTJ; Somi S; van Houwelingen KG; Stoel MG; de Man FHAF; Louwerenburg JHW; Hartmann M; Zocca P; Linssen GCM; van der Palen J; Doggen CJM; Löwik MM
    Lancet; 2016 Nov; 388(10060):2607-2617. PubMed ID: 27806902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease.
    Tada T; Byrne RA; Cassese S; King L; Schulz S; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2013 Jan; 165(1):80-6. PubMed ID: 23237137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
    Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
    Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
    Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.